ReviewMediators of inflammation2012
Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.
Review in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- The immunomodulatory and antitumor properties of the bacterial metalloprotease Oligopeptidase A are mediated by TLR4/MyD88/TRIF and MAPK signaling pathways.Frontiers in immunology · 2025Article
- The current role of dendritic cells in the progression and treatment of colorectal cancer.Cancer biology & medicine · 2024Review
- The role of dendritic cells in COVID-19 infection.Emerging microbes & infections · 2023Review
- Article
- The role of dendritic cells in the immunomodulation to implanted biomaterials.International journal of oral science · 2022Review
- Crosstalk between estrogen, dendritic cells, and SARS-CoV-2 infection.Reviews in medical virology · 2022Review
- Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy.Frontiers in immunology · 2022Review
- The Role of Dendritic Cells during Physiological and Pathological Dentinogenesis.Journal of clinical medicine · 2021Review
- Made to Measure: Patient-Tailored Treatment of Multiple Sclerosis Using Cell-Based Therapies.International journal of molecular sciences · 2021Review
- Multi-Level Computational Modeling of Anti-Cancer Dendritic Cell Vaccination Utilized to Select Molecular Targets for Therapy Optimization.Frontiers in cell and developmental biology · 2021Article
- Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.Frontiers in immunology · 2021Review
- Current Trends in Cancer Immunotherapy.Biomedicines · 2020Review
- Brain immunology and immunotherapy in brain tumours.Nature reviews. Cancer · 2020Review
- The function of dendritic cells in modulating the host response.Molecular oral microbiology · 2018Review
- Dendritic cell-based immunotherapy: a basic review and recent advances.Immunologic research · 2017Review
- Epstein Barr virus Latent Membrane Protein-1 enhances dendritic cell therapy lymph node migration, activation, and IL-12 secretion.PloS one · 2017Article
- Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.Methods in molecular biology (Clifton, N.J.) · 2016Article
- Review
- Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage.Journal of immunology research · 2015Review
- Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.Frontiers in immunology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Earlier investigations have revealed a surprising complexity and variety in the range of interaction between cells of the innate and adaptive immune system. Our understanding of the specialized roles of dendritic cell (DC) subsets in innate and adaptive immune responses has been significantly advanced over the years. Because of their immunoregulatory capacities and because very small numbers of activated DC are highly efficient at generating immune responses against antigens, DCs have been vigorously used in clinical trials in order to elicit or amplify immune responses against cancer and chronic infectious diseases. A better insight in DC immunobiology and function has stimulated many new ideas regarding the potential ways forward to improve DC therapy in a more fundamental way. Here, we discuss the continuous search for optimal in vitro conditions in order to generate clinical-grade DC with a potent immunogenic potential. For this, we explore the molecular and cellular mechanisms underlying adequate immune responses and focus on most favourable DC culture regimens and activation stimuli in humans. We envisage that by combining each of the features outlined in the current paper into a unified strategy, DC-based vaccines may advance to a higher level of effectiveness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.